Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: A GPRD study

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 1, 2013, Pages 15-21

  Alexandropoulou, Kalliopi ^a   Van Vlymen, Jeremy ^b   Reid, Fiona ^b   Poullis, Andrew ^b   Kang, Jin Yong ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b NONE

Author keywords

Barrett's oesophagus; Gastro oesophageal reflux; General Practice Research Database; Incidence; Oesophageal cancer; Proton pump inhibitors

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; ESOPHAGUS CANCER; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; CHILD; CHILD, PRESCHOOL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; ENGLAND; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; GENERAL PRACTICE; HISTAMINE H2 ANTAGONISTS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRECANCEROUS CONDITIONS; PREVALENCE; PROTON PUMP INHIBITORS; SEX DISTRIBUTION; TIME FACTORS; TREATMENT OUTCOME; WALES; YOUNG ADULT;

EID: 84870936814     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283595086     Document Type: Article

References (43)

1. Bardhan KD, Royston C, Nayyar AK. Reflux rising! An essay on witnessing a disease in evolution [see comment]. Dig Liver Dis 2006; 38:163-168.
2. El Serag HB. Time trends of gastroesophageal reflux disease: a systematic review [review]. Clin Gastroenterol Hepatol 2007; 5:17-26.
3. Dent J, el Serag HB, Wallander MA, Johansson S. Epidemiology of gastrooesophageal reflux disease: a systematic review [review]. Gut 2005; 54:710-717.
4. Hampel H, Abraham NS, El Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143:199-211.
5. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999; 106:642-649.
6. Roosendaal R, Kuipers EJ, Buitenwerf J, van Uffelen C, Meuwissen SG van Kamp GJ, Vandenbroucke-Grauls CM. Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 1997; 92:1480-1482.
7. El Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43:327-333.
8. Ho KY, Chan YH, Kang JY. Increasing trend of reflux esophagitis and decreasing trend of Helicobacter pylori infection in patients from a multiethnic Asian country. Am J Gastroenterol 2005; 100:1923-1928.
9. Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000; 95:387-394.
10. Ruigomez A, Garcia Rodriguez LA, Wallander MA, Johansson S, Graffner H, Dent J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther 2004; 7:751-760.
11. Kahrilas PJ, Lin S, Chen J, Manka M. The effect of hiatus hernia on gastro-oesophageal junction pressure [see comment]. Gut 1999; 44: 476-482.
12. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 1999; 94:2054-2059.
13. Penagini R, Carmagnola S, Cantu P. Review article: gastro-oesophageal reflux disease - pathophysiological issues of clinical relevance [review]. Aliment Pharmacol Ther 2002; 16 (Suppl 4):65-71.
14. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000; 14:1589-1594.
15. Wiklund I, Carlsson J, Vakil N. Gastroesophageal reflux symptoms and wellbeing in a random sample of the general population of a Swedish community. Amn J Gastroenterol 2006; 101:18-28.
16. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report [see comment]. Scand J Gastroenterol 2005; 40:275-285.
17. Reid BJ. Barrett's esophagus and esophageal adenocarcinoma [review]. Gastroenterol Clin North Am 1991; 4:817-834.
18. Westhoff B, Brotze S, Weston A, McElhinney C, Cherian R, Mayo MS, et al. The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 2005; 61:226-231.
19. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma [see comment]. N Engl J Med 1999; 340:825-831.
20. Office for National Statistics. Cancer statistics registrations: registrations of cancer diagnosed in 2005, England. Series MB1 no. 36. Office for National Statistics. 2008.
21. Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A. Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971-1998/1999. Aliment Pharmacol Ther 2003; 17:655-664.
22. Bretagne JF, Honnorat C, Richard-Molard B, Caekaert A, Barthelemy P. Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther 2006; 23:607-616.
23. Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101:2128-2138.
24. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999; 49:451-453.
25. Delaney BC. Review article: prevalence and epidemiology of gastrooesophageal reflux disease [review]. Aliment Pharmacol Ther 1920;2-4.
26. Walley T, Mantgani A. The UK General Practice Research Database [see comment]. Lancet 1997; 350:1097-1099.
27. Rodriguez LAG, Ruigomez A, Wallander MA, Johansson S, Stalhammar N. Health resource utilisation and drug treatment pattern in a cohort of patients with a first episode of gastroesophageal reflux disease. Pharmacoepidemiol Drug Saf 1999; 8:493-500.
28. Johansson S, Wallander MA, Ruigomez A, Garcia Rodriguez LA. Is there any association between myocardial infarction, gastro-oesophageal reflux disease and acid-suppressing drugs? Aliment Pharmacol Ther 2003; 18:973-978.
29. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 30:766-768.
30. Ruigomez A, Garcia Rodriguez LA, Wallander MA, Johansson S, Dent J. Comparison of gastro-oesophageal reflux disease and heartburn diagnoses in UK primary care. Curr Med Res Opin 2006; 22:1661-1668.
31. Prach AT, MacDonald TA, Hopwood DA, Johnston DA. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 1997; 350:933.
32. Conio M, Cameron AJ, Romero Y, Branch C, Schleck C, Burgart L, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001; 48:304-309.
33. Caygill CP, Reed PI, Johnston BJ, Hill MJ, Ali MH, Levi S. A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. Eur J Gastroenterol Hepatol 1999; 11:1355-1358.
34. Van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005; 54:1062-1066.
35. British Society of Gastroenterology (BSG). Dyspepsia management guidelines. BSG guidelines in gastroenterology. Glasgow: British Society of Gastroenterology; 1996.
36. British Society of Gastroenterology (BSG). Dyspepsia management guidelines. Glasgow: British Society of Gastroenterology; 2002.
37. National Institute for Clinical Excellence (NICE). Dyspepsia: managing dyspepsia in adults in primary care. Centre for Health Services Research Report No 112 [ISBN: 0-9540161-7-3]. University of Newcastle upon Tyne, 2004. Available at: http://www.nice.org.uk/pdf/CG017fullguideline.pdf [Accessed 17 September 2012].
38. Garcia Rodriguez LA, Perez GS. Use of the UK general practice research database for pharmacoepidemiology [see comment]. Br J Clin Pharmacol 1998; 45:419-425.
39. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux [see comment]. Gut 2004; 53:1070-1074.
40. Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK [see comment]. Gut 2006; 55:1538-1544.
41. Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison DJ, McColl KEL. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut 2009; 58:16-23.
42. Lofdahl HE, Lu Y, Lagergren J. Sex-specific risk factor profile in oesophageal adenocarcinoma. Br J Cancer 2008; 99:1506-1510.
43. Kang JY, Tinto A, Higham J, Majeed A. Peptic ulceration in general practice in England and Wales 1994-98: period prevalence and drug management. Aliment Pharmacol Ther 2002; 16:1067-1074.